Form 4: BIOXYTRAN Director Boosts Preferred Share Holdings

BIOXYTRAN Director Dale H. Conaway reported two separate acquisitions of preferred shares, increasing his beneficial ownership to 379,177 shares.

Summary

• Dale H. Conaway, a Director of BIOXYTRAN, INC (BIXT), reported changes in his beneficial ownership of preferred securities.
• On August 12, 2025, Mr. Conaway acquired 10,417 preferred shares at a price of $0.485 per share.
• Following this transaction, his direct beneficial ownership of preferred shares increased to 340,589.
• On November 14, 2025, Mr. Conaway acquired an additional 38,588 preferred shares at a price of $0.35 per share.
• After the second transaction, his total direct beneficial ownership of preferred shares reached 379,177.

Sentiment

Score: 7

Explanation: The sentiment is positive due to a director increasing their stake in the company, which typically indicates confidence in future performance.

Positives

• A Director's acquisition of additional shares signals confidence in the company's future prospects and valuation.
• The two purchases demonstrate a continued commitment by a key insider to increase their stake in BIOXYTRAN.

Industry Context

Insider buying, particularly by a director, is often interpreted by the market as a positive signal, suggesting that those closest to the company believe its shares are undervalued or that significant positive developments are anticipated. This can potentially boost investor confidence in the biotechnology sector, where company-specific news often drives sentiment.

Related Party Transactions

• Director Dale H. Conaway acquired 10,417 preferred shares on 08/12/2025 at $0.485 per share.
• Director Dale H. Conaway acquired 38,588 preferred shares on 11/14/2025 at $0.35 per share.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive indicator of management's belief in the company's value, potentially leading to increased investor confidence.
• The transactions could influence market perception and trading activity for BIOXYTRAN's stock.

Key Dates

Recommendation

The director's decision to increase their personal stake in BIOXYTRAN through two separate purchases of preferred shares suggests strong insider confidence in the company's future prospects. This action, often seen as a bullish signal, indicates that management believes the stock is undervalued or expects positive developments. While a single Form 4 is not a definitive buy signal, it provides a compelling reason for investors to consider a 'buy' recommendation, especially when combined with other positive fundamentals.

Keywords

BIOXYTRAN, BIXT, Insider Trading, Form 4, Beneficial Ownership, Director Share Purchase, Preferred Stock, Equity Acquisition